Barinthus Biotherapeutics PLC BRNS
At closeSep 8, 2026, 4:00 PM EDT
After hours · Sep 8, 4:00 PM ET
- YTD
- +5.73%
- 1 year
- -19.82%
- Market cap
- 44.65M
- Revenue (ttm)
- 14.97M
- EPS (ttm)
- -1.49
- Shares out
- 40.23M
- Forward P/E
- -0.62
- YTD return
- +5.73%
- 1-year return
- -19.82%
- Volume
- 376.14K
- Avg volume
- 54.43K
- Open
- 0.7443
- Previous close
- 0.759
- Day's range
- 0.6421 – 0.7629
- 52-week range
- 0.801 – 4.16
- Beta
- -0.58
- Price target
- 7.25 (+879.6%)
- Earnings date
- Aug 8, 2024
2Y 0.0000 (0.00%)
Key statistics
- Enterprise value
- -48.61M
- PEG ratio
- 0.00
- Price / sales
- 2.98
- Price / book
- 0.28
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -50.75M
- Total cash
- 106.10M
- Total debt
- 12.67M
- Return on equity
- -32.60%
- Short % of float
- 0.06%
- 50-day average
- 1.16
- 200-day average
- 1.66
Analyst view
- Target (low)
- 5.00
- Target (mean)
- 7.25
- Target (high)
- 9.50
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.41.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.45 | -0.21 | +0.24 | +53.33% |
| Aug 8, 2024 | Jun 1, 2024 | -0.42 | -0.43 | -0.01 | -2.38% |
| Aug 8, 2024 | Jun 1, 2024 | -0.42 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.64 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.64 | -0.40 | +0.24 | +37.50% |
| Mar 20, 2024 | Dec 1, 2023 | -0.55 | -0.45 | +0.10 | +18.18% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2024 | Alliance Global Partners | main | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Barinthus Biotherapeutics PLC
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- barinthusbio.com
News
Is Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Stock Outpacing Its Medical Peers This Year? 
Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics 
Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments 
12 Health Care Stocks Moving In Monday's Intraday Session 
12 Health Care Stocks Moving In Monday's Pre-Market Session - 12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session - 12 Health Care Stocks Moving In Monday's After-Market Session
Are KW, BRNS, AFBI Obtaining Fair Deals for their Shareholders? 
Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS
Your note
Sign in to keep a note on BRNS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ENRIGHT WILLIAM | Chief Executive Officer | Sale | Mar 26, 2023 | 0 |
| SCHEEREN JOSEPH | Director | Purchase | Jun 25, 2023 | 23,000 |
| WRIGHT ROBIN | Director | Purchase | May 24, 2023 | 48,256 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| M&G Plc | 12.92% | 5,197,349 | 5.77M | Sep 29, 2024 |
| Alphabet Inc. | 3.76% | 1,513,644 | 1.68M | Sep 29, 2024 |
| HSG Holding Ltd. | 3.53% | 1,420,473 | 1.58M | Sep 29, 2024 |
| DC Funds, LP | 1.60% | 642,204 | 712.85K | Sep 29, 2024 |
| BlueCrest Capital Management Ltd | 1.35% | 542,673 | 602.37K | Sep 29, 2024 |
| Johns Hopkins University | 0.30% | 122,237 | 135.68K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.03% | 11,568 | 12.84K | Oct 30, 2024 |